OncoSec Medical Incorporated
ONCS
ONCS was delisted on the 23rd of June, 2023.
20 hedge funds and large institutions have $1.57M invested in OncoSec Medical Incorporated in 2019 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 17 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
16% less capital invested
Capital invested by funds: $1.86M → $1.57M (-$288K)
33% less funds holding
Funds holding: 30 → 20 (-10)
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$691K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$356K |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
+$185K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$172K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$166K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$280K |
| 2 |
BlackRock
New York
|
-$66K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$32K |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$32K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$32K |
ONCS Hedge Fund Activity: Q2 2019 in Review
20 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in OncoSec Medical Incorporated (ONCS) for Q2 2019, worth a combined $1.57M — down 16% from $1.86M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ONCS and 7 opened new positions — a net loss of 10 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was 683 Capital Management, adding an estimated $691K. The largest seller was Intrinsic Edge Capital Management, exiting entirely with an estimated $280K sold.
- 20 institutional investors held OncoSec Medical Incorporated (ONCS) as of Q2 2019, down from 30 in Q1 2019.
- Funds reported $1.57M of OncoSec Medical Incorporated stock for Q2 2019, down 16% quarter-over-quarter.
- 7 funds opened new OncoSec Medical Incorporated positions in Q2 2019 and 17 closed out, a net change of -10 holders.
- The largest OncoSec Medical Incorporated buyer in Q2 2019 was 683 Capital Management, an estimated $691K added.
- The largest OncoSec Medical Incorporated seller in Q2 2019 was Intrinsic Edge Capital Management, an estimated $280K sold.
Based on aggregated 13F filings for Q2 2019.